Market closedNon-fractional
Medpace/MEDP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Medpace
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Ticker
MEDP
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
Cincinnati, United States
Employees
5,800
Website
www.medpace.com
Medpace Metrics
BasicAdvanced
$12B
Market cap
35.74
P/E ratio
$10.64
EPS
1.36
Beta
-
Dividend rate
Price and volume
Market cap
$12B
Beta
1.36
Financial strength
Current ratio
0.879
Quick ratio
0.818
Long term debt to equity
17.26
Total debt to equity
17.26
Management effectiveness
Return on assets (TTM)
14.33%
Return on equity (TTM)
58.86%
Valuation
Price to earnings (TTM)
35.745
Price to revenue (TTM)
5.772
Price to book
15.38
Price to tangible book (TTM)
177.62
Price to free cash flow (TTM)
23.305
Growth
Revenue change (TTM)
21.36%
Earnings per share change (TTM)
27.33%
3-year revenue growth (CAGR)
25.45%
3-year earnings per share growth (CAGR)
31.90%
What the Analysts think about Medpace
Analyst Ratings
Majority rating from 8 analysts.
Medpace Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$511M
2.53%
Net income
$103M
31.07%
Profit margin
20.05%
27.79%
Medpace Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.93
$2.22
$2.46
$3.20
-
Expected
$1.91
$2.05
$2.22
$2.47
$2.53
Surprise
0.79%
8.50%
10.71%
29.82%
-
Medpace News
AllArticlesVideos
Medpace Being Investigated on Behalf of Medpace Holdings, Inc. Investors. Contact Levi & Korsinsky For Details.
Accesswire·16 hours ago
ATTENTION MEDP SHAREHOLDERS: Investors who lost money on Medpace Holdings, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Accesswire·2 days ago
NXP Semiconductors Posts Mixed Q2 Results, Joins Medpace And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
Benzinga·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Medpace stock?
Medpace (MEDP) has a market cap of $12B as of July 27, 2024.
What is the P/E ratio for Medpace stock?
The price to earnings (P/E) ratio for Medpace (MEDP) stock is 35.74 as of July 27, 2024.
Does Medpace stock pay dividends?
No, Medpace (MEDP) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Medpace dividend payment date?
Medpace (MEDP) stock does not pay dividends to its shareholders.
What is the beta indicator for Medpace?
Medpace (MEDP) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Medpace stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.